Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-230317 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Sid E O'Bryant und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Celecoxib, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was the first-ever large-scale anti-inflammatory prevention trial targeting Alzheimer’s disease.
Objective
The overall goal of this study was to evaluate predictive blood biomarker profiles that identified individuals most likely to be responders on NSAID treatment or placebo at 12 and 24 months.
Methods
Baseline (n = 193) and 12-month (n = 562) plasma samples were assayed. The predictive biomarker profile was generated using SVM analyses with response on treatment (yes/no) as the outcome variable.
Results
Baseline (AUC = 0.99) and 12-month (AUC = 0.99) predictive biomarker profiles were highly accurate in predicting response on Celecoxib arm at 12 and 24 months. The baseline (AUC = 0.95) and 12-month (AUC = 0.9) predictive biomarker profile predicting response on Naproxen were also highly accurate at 12 and 24 months. The baseline (AUC = 0.93) and 12-month (AUC = 0.99) predictive biomarker profile was also highly accurate in predicting response on placebo. As with our prior work, the profiles varied by treatment arm.
Conclusions
The current results provide additional support for a precision medicine model for treating and preventing Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
- Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
- Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
- Department of Medicine, Johns Hopkins School of Medicine, Baltimore, USA.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
O'Bryant, S. E., Zhang, F., Johnson, L. A., Hall, J., Petersen, M., Oh, E. S., Lyketsos, C. G., & Rissman, R. A. (2023). Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230317
Vancouver
O'Bryant SE, Zhang F, Johnson LA, Hall J, Petersen M, Oh ES, et al. Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-230317
BibTeX
@article{OBryant2023,
author = {O'Bryant, Sid E and Zhang, Fan and Johnson, Leigh A and Hall, James and Petersen, Melissa and Oh, Esther S and Lyketsos, Constantine G and Rissman, Robert A},
title = {Precision Medicine for Preventing Alzheimer’s Disease: Analysis of the ADAPT Study},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-230317}
}
EUVIMED